Wat is de prijs voor Novan, Inc. (NOVN)

Het prijs van Novan, Inc. (NOVN) is $0.056

Wat is de marktkapitalisatie voor Novan, Inc. (NOVN)

Marktkapitalisatie voorNovan, Inc. (NOVN) is $451.38K

Novan, Inc. (NOVN) Dividendrendement

Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.

Jaar	Dividendrendement	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Dividendrendement

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Dividendrendement	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	0.65%	BE

Bedrijf

Dividendrendement

Land